The U.S. Food and Drug Administration on November 16 authorized a virtual reality system from Applied VR for reducing lower back pain after a majority of patients in a trial testing the device showed lesser discomfort.
The U.S. Food and Drug Administration approved Novartis’ Cosentyx (secukinumab) for the treatment of active non-radiographic axial spondyloarthritis.
Nektar Therapeutics withdrew the application for the company’s opioid painkiller for adults with chronic low back pain, after a U.S. Food and Drug Administration panel unanimously voted against the drug’s approval.
With an opioid molecule awaiting regulatory review, Nektar Therapeutics announced the launch of Inheris Biopharma, which will be responsible for the commercialization of NKTR-181.
A non-opioid painkiller developed by Pfizer Inc. and Eli Lilly and Co. succeeded in reducing chronic low back pain when used in a stronger dose, results from a late-stage study showed.
The U.S. Food and Drug Administration’s Anesthetic and Analgesic Drug Products Advisory Committee voted to recommend AcelRx Pharmaceuticals’ Dsuvia to manage moderate-to-severe pain.
People who exercise may lower their odds of developing low back pain or may reduce the intensity of back pain they do experience, a research review suggests.
Pfizer Inc. and Eli Lilly and Company announced that the U.S. Food and Drug Administration granted Fast Track designation for tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP).
Spine surgeons are noticing an increase in patients with neck and upper back pain, likely related to poor posture during prolonged smartphone use, according to a recent report.
Regeneron and partner Teva said the U.S. health regulator placed a clinical hold on a mid-stage study of their experimental drug for chronic lower back pain.